Clinical trials: Alcohol Use Disorder, Severe
Major Depressive Disorder, Alcohol Use Disorder
Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.
- Trial name
- NCT03658330
- Testing
- Ketamine + Naltrexone
- Volunteers
- 5 people
- Sponsor
- VA Connecticut Healthcare System
Alcohol Abuse
Perception of the Risks of Alcohol and Individual Vulnerabilities in Young Adults
Alcohol use is the second leading cause of preventable death after smoking. The Evin law was built in 1991 with the goal of reducing exposure to alcohol marketing among the youngest.
- Trial name
- DEPREV (NCT03876132)
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Brest
Alcohol Use Disorder, Severe
Inpatient Single Dose Interventions for Alcohol Use Disorder
Every year, alcohol use disorder (AUD) generates millions of emergency department (ED) visits and hospital admissions, costing the U.S. health sector over $90 billion.
- Trial name
- NCT04562779
- Testing
- Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Denver Health and Hospital Authority
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
LHC-CIDI-5 in Hong Kong
The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12…
- Conditions
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD), Suicidal Ideation
- Trial name
- NCT06804525
- Testing
- CIDI-5, LHC-CIDI-5
- Where
- Hong Kong
- Volunteers
- 2,500 people
- Sponsor
- The University of Hong Kong
Alcoholic Hepatitis
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive…
- Trial name
- NCT05294744
- Testing
- N-acetylcysteine
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Bioaraba Health Research Institute
Depression - Major Depressive Disorder, Anxiety
Deaf CBT-TS to Reduce Suicide Risk
The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase…
- Conditions
- Depression - Major Depressive Disorder, Anxiety, PTSD - Post Traumatic Stress Disorder, Insomnia
- Trial name
- NCT07279363
- Testing
- Deaf CBT-TS
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Rochester
Major Depressive Disorder, Alcohol Use Disorder
Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.
The purpose of this study is to look at the safety of a study treatment with stem cells in Alcohol Use Disorder And Major Depression (AUD-MD) subjects.
- Trial name
- Alaunus (NCT03265808)
- Testing
- allogeneic human mesenchymal stem cells (allo-hMSCs)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Ihsan M Salloum, MD, MPH
Alcohol Use Disorder
ED Initiated Oral Naltrexone for AUD
This study will recruit Emergency Department (ED) patients with moderate to severe alcohol use disorder (AUD) who are interested in initiating medication assisted treatment (MAT). The study is split into two phases.
- Trial name
- NCT04817410
- Testing
- Emergency Department Initiated Oral Naltrexone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alcohol Use Disorder
Severe Alcohol-use Disorder: a tDCS and Response Inhibition Training Intervention
Most severe forms of alcohol-use disorder are thought to reflect an abnormal interplay between two neural systems: an overly active impulsive one driven by immediate rewards prospects and a weak reflective one, tuned on long-term…
- Trial name
- ALCOSTIM (NCT03447054)
- Testing
- Combined TDCS active and ICT active, Combined TDCS active and ICT inactive
- Where
- Belgium
- Volunteers
- 136 people
- Sponsor
- Brugmann University Hospital
Alcohol Use Disorder, Severe
Impact of Omega 3 in Alcohol Use Disorder
The goal of this clinical trial is to investigate the biological pathways underlying the beneficial effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) on mental health in patients with alcohol use disorder.
- Trial name
- W3-AUD (NCT05899660)
- Testing
- Active Comparator: Omega-3
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Université Catholique de Louvain
Major Depressive Disorder, Alcohol Use Disorder
Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Mirtazapine is a non-SSRI (selective serotonin reuptake inhibitor) medication with a unique structure and mechanism of action. Recent study results suggest that mirtazapine may be more effective and faster acting than other…
- Trial name
- PT-MAD (NCT02185131)
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pittsburgh
Alcohol Use Disorder, Alcoholic Hepatitis
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant…
- Trial name
- NCT03845205
- Testing
- Integrated AUD Treatment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Depression - Major Depressive Disorder, Schizophenia Disorder
A Novel Blood Test as a Biomarker in Mental Health
This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital…
- Conditions
- Depression - Major Depressive Disorder, Schizophenia Disorder, Psychosis, Mania (Neurotic)
- Trial name
- LEADING-MH (NCT06856161)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Fraser Health
Disease, Mental Disorders, Severe
Multifamily Group Psychoeducation for SUD's in Turkey
The aim of this study is to investigate the effects of multi-family group psychoeducation (MFGP) on the families of people living with a diagnosis of substance abuse disorder on patients and their families.
- Conditions
- Disease, Mental Disorders, Severe, Substance-Related Disorders, Substance Use Disorders
- Trial name
- NCT05564559
- Testing
- multifamily group psychoeducation
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Ege University
Alcoholic Hepatitis
Prothrombin Time Predicts Steroid Response in Severe Alcoholic Hepatitis.
Alcoholic hepatitis (AH) is the most severe form of acute alcohol-related liver disease. Maddrey's discriminant function (mDF) >32 defines the severe form of AH, which is associated with a high mortality.
- Trial name
- AH2023 (NCT05883891)
- Testing
- prothrombin time
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Alcohol Use Disorder
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder
This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison…
- Trial name
- NCT07296094
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Brigham and Women's Hospital
Alcohol Use Disorder
Study of Sunobinop on Craving in Alcohol Use Disorder
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.
- Trial name
- NCT06545929
- Testing
- Sunobinop
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Knoa Pharma LLC
Alcohol Abuse, Alcohol Use Disorder
The Effect of Comorbid Alcohol/Substance Use
Study Design This study was designed as a comparative, cross-sectional case-control study examining the effect of comorbid alcohol and substance use disorder (ASUD) on clinical course and social inclusion among individuals with…
- Conditions
- Alcohol Abuse, Alcohol Use Disorder, Substance Use Disorders, Severe Mental Disorder
- Trial name
- NCT07692984
- Testing
- case (comorbid diagnosis), control
- Where
- Turkey (Türkiye)
- Volunteers
- 297 people
- Sponsor
- Abant Izzet Baysal University
Severe Alcohol Use Disorder (DSM 5)
Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH
Randomized clinical trial of 11 days Cannabidiol versus placebo as an adjunctive treatment during inpatient alcohol detoxification to improve abstinence in patients with severe alcohol use disorder.
- Trial name
- CBD-OH (NCT05860699)
- Testing
- Half dose CBD, Full dose CBD
- Where
- 12 sites in France
- Volunteers
- 210 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Disorder, Alcohol Use Disorder
Cognitive Dysfunction in the Addictions Study - Project 4 (P4)
The prefrontal cortex, although well established as an efficacious target for the treatment of major depressive disorder (MDD), has recently come into favour as a therapeutic target for alcohol use disorders (AUD).
- Trial name
- CDiA-P4 (NCT06299787)
- Testing
- intermittent theta burst stimulation
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health